GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

AGIO · Mar 31, 2026

AGIOS PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001439222-26-000073General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

3.71% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-573.22% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

137.75% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

169.13% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

93.64% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-530.34% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

391.15% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

74.91% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History9 statesHistory building

Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20250/8 normalizedLevel 3 Mar 31, 20260/8 normalizedLevel 3 Jun 30, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 7.99%
Current: 3.71%
Delta: -4.28%

Cash Generation Increased

Previous: -690.34%
Current: -573.22%
Delta: 117.12%

Growth Increased

Previous: 48.03%
Current: 137.75%
Delta: 89.72%

Inventory Pressure Increased

Previous: 60.93%
Current: 169.13%
Delta: 108.20%

Margin Increased

Previous: 88.26%
Current: 93.64%
Delta: 5.39%

Profitability Increased

Previous: -873.87%
Current: -530.34%
Delta: 343.52%

R And D Intensity Decreased

Previous: 628.44%
Current: 391.15%
Delta: -237.29%

Sbc Intensity Decreased

Previous: 97.27%
Current: 74.91%
Delta: -22.36%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · AGIO Fundamental State →Transitioned To · AGIO CAPEX_INTENSITY_DECREASED →Transitioned To · AGIO CASH_GENERATION_INCREASED →Transitioned To · AGIO GROWTH_INCREASED →Transitioned To · AGIO INVENTORY_PRESSURE_INCREASED →Transitioned To · AGIO MARGIN_INCREASED →Transitioned To · AGIO PROFITABILITY_INCREASED →Transitioned To · AGIO R_AND_D_INTENSITY_DECREASED →Transitioned To · AGIO SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.